Advanced searches left 3/3

Cd4+ cd8+ ratio - Astrophysics Data System

Summarized by Plex Scholar
Last Updated: 12 October 2021

* If you want to update the article please login/register

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

Pleural effusion is an unusual immune-related negative occasion for lung cancer cells patients getting immune checkpoint preventions. We registered 281 lung cancer patients treated with ICIs and 17 were evaluated. We classified the formation of pleural effusion into 3 patterns: type 1, substantial and fast; type 2, slow-moving and indolent; and type 3, with illness development. Many patients of types 1 and 2 effusions had pleural effusion with CD4/CD8 proportions ≥ 1. 93. The median OS time in type 1, 2, and 3 patients were not gotten to, 24. 8, and 2. 6 months, specifically. The typical PFS time in type 1, 2, and 3 patients were 35. 5, 30. 2, and 1. 4 months, specifically. The typical PFS of those with pleural effusion CD4/CD8 ≥ 1. 93 and < 1. 93 were 18. 4 and 1. 2 months. In verdict, patients with type 1 and 2 effusion patterns had better survival than those with type 3.

Source link: https://ui.adsabs.harvard.edu/abs/2021NatSR..11.9381L/abstract


Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers

Low CD4+ cell count in patients with human immunodeficiency infection and hepatitis B virus coinfection throughout combination antiretroviral therapy has been explained; nonetheless, especially couple of studies have examined coinfected patients positive for antibodies to the HBV c antigen. A substantial boost in the absolute count of CD8+ T lymphocytes was defined from months 2 to 24 from the beginning of cART in the subgroup of HBV coinfected patients with an AIDS occasion at the onset of HIV infection. A substantial boost in the CD8 T cell count was revealed up to 24 months after the initiation of reliable cART in the subgroup of patients with the worst immune condition.

Source link: https://ui.adsabs.harvard.edu/abs/2021NatSR..11.3965M/abstract

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions